Anabolic Tesamorelin Peptides Lyophilized Powder Intramuscular Injection
|CAS No.:||901758-09-6||Other Names:||GHRF||MF:||C221H366N72O67S|
|EINECS No.:||N/A||Place of Origin:||ShangHai, China (Mainland)||Type:||Immune Function Agents, Vitamins, Amino Acids and Coenzymes|
|Grade Standard:||Medicine Grade||Usage:||Animal Pharmaceuticals|
|Purity:||98%min, 99%||Product Name:||Tesamorelin|
|Molecular Formula:||C221H366N72O67S||Appearance:||White powder||Dry:||Freeze|
|Assay:||HPLC 99%||Package`:||10 mg/vial||Other Name:||GHRF|
1. Triptorelin raises testosterone levels by causing constant stimulation of the pituitary, it decreases pituitary secretion of gonadotropins luteinizing hormone (LH) and follicle stimulating hormone (FSH).
2. Like other GnRH agonists, triptorelin may be used in the treatment of hormone-responsive cancers such as prostate cancer or breast cancer, precocious puberty,estrogen-dependent conditions (such as endometriosis or uterine fibroids), and in assisted reproduction.
Tesamorelin is a stabilized analogue of the g h-releasing factor (GRF) that induces (GH) in a specific and physiological manner. To date, clinical studies suggest that Tesamorelin reduces visceral fat in HIV-infected patients with abdominal lipo-hypertrophy as well as reducing abdominal fat in all individuals studied.
A peptide that increases gh release improved several measures of cognitive function in cognitively normal and mildly impaired older individuals in a placebo-controlled trial, a researcher said here. Scores on standard tests of executive function and verbal memory were significantly higher in participants given tesamorelin (Egrifta), a synthetic analog of gh releasing hormone (GHRH), in a 20-week trial, according to Laura D. Baker, PhD.. Participants taking the drug in the 78-person trial also reported greater subjective improvement in cognition relative to the placebo group.
In animal studies, GHRH administration improved biomarkers of brain function as well as performance on cognition tests. And a 2006 clinical trial with GHRH found small but significant improvements in cognitive test scores in healthy older adults. In the current study, funded by the National Institute on Aging, 41 cognitively normal adults and 37 with mild cognitive impairment were randomized to placebo or tesamorelin at 1 mg/day subcutaneously.
|CJC1294 with DAC||2mg||98%|
|Contact Person :||Miss. Anne|